Arcus Historical Balance Sheet

RCUS Stock

USD 10.89 1.01 10.22%

Trend analysis of Arcus Biosciences balance sheet accounts such as Other Liabilities of 456.4 M, Net Tangible Assets of 793.3 M, Property Plant And Equipment Net of 40.9 M or Accounts Payable of 11.8 M provides information on Arcus Biosciences' total assets, liabilities, and equity, which is the actual value of Arcus Biosciences to its prevalent stockholders. By breaking down trends over time using Arcus Biosciences balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.

Cash Flow Balance Sheet Income Statement

Covid

Financial Statement Analysis is much more than just reviewing and examining Arcus Biosciences latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Arcus Biosciences is a good buy for the upcoming year.

Arcus Biosciences Inventory

(162.54 Million)

Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Arcus Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in employment.

For more information on how to buy Arcus Stock please use our How to Invest in Arcus Biosciences guide.

About Arcus Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of Arcus Biosciences at a specified time, usually calculated after every quarter, six months, or one year. Arcus Biosciences Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Arcus Biosciences and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Arcus currently owns. An asset can also be divided into two categories, current and non-current.

Arcus Biosciences Balance Sheet Chart

At this time, Arcus Biosciences' Property Plant Equipment is comparatively stable compared to the past year. Short Term Debt is likely to gain to about 18 M in 2025, whereas Total Current Liabilities is likely to drop slightly above 115.9 M in 2025.

Total Assets Other Current Liab Total Current Liabilities Total Stockholder Equity Short Term Investments Capital Lease Obligations

Add Fundamental

Total Assets

Total assets refers to the total amount of Arcus Biosciences assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Arcus Biosciences books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Total Current Liabilities

Total Current Liabilities is an item on Arcus Biosciences balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Arcus Biosciences are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Total Stockholder Equity

The total equity held by shareholders, calculated as the difference between a company's total assets and total liabilities. It represents the net value of the company owned by shareholders.

Short Term Investments

Short Term Investments is an item under the current assets section of Arcus Biosciences balance sheet. It contains any investments Arcus Biosciences undertook that will expire in less than one year. These accounts contain financial instruments such as stocks or bonds that Arcus Biosciences can easily liquidate in the marketplace.

Capital Lease Obligations

Arcus Biosciences capital lease obligations are the amount due for long-term lease agreements that are nearly equivalent to Arcus Biosciences asset purchases. For example, Arcus Biosciences can use a capital lease to finance the purchase of an asset without ever buying it. A capital lease gives companies such as Arcus Biosciences control over an asset for a big portion of its life. The total obligations of a company under capital leases, which are lease agreements that transfer substantially all risks and rewards of ownership to the lessee.

Most accounts from Arcus Biosciences' balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Arcus Biosciences current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Arcus Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in employment.

For more information on how to buy Arcus Stock please use our How to Invest in Arcus Biosciences guide.At this time, Arcus Biosciences' Property Plant Equipment is comparatively stable compared to the past year. Short Term Debt is likely to gain to about 18 M in 2025, whereas Total Current Liabilities is likely to drop slightly above 115.9 M in 2025.

	2022	2023	2024	2025 (projected)
Other Current Liabilities	73M	65M	122M	128.1M
Total Assets	1.3B	1.1B	1.2B	822.9M

Other Current Liab Total Assets

Arcus Biosciences balance sheet Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Net Tangible Assets	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Cash And Short Term Investments	Net Receivables	Common Stock Shares Outstanding	Short Term Investments	Non Current Liabilities Total	Capital Surpluse	Other Current Assets	Other Stockholder Equity	Total Liab	Long Term Investments	Property Plant And Equipment Gross	Preferred Stock Total Equity
Total Assets		0.78	0.95	0.98	0.94	0.95	0.85	-0.26	-0.71	0.87	0.89	0.81	0.76	0.78	0.93	0.6	0.93	0.87	0.99	0.92	0.72	0.45	0.99	0.84	0.9	0.7
Other Current Liab	0.78		0.86	0.71	0.92	0.88	0.53	-0.43	-0.96	0.81	0.74	0.45	0.4	0.66	0.83	0.19	0.86	0.84	0.79	0.92	0.96	0.01	0.81	0.41	0.67	0.56
Total Current Liabilities	0.95	0.86		0.9	0.93	0.93	0.69	-0.43	-0.84	0.95	0.89	0.62	0.56	0.85	0.97	0.38	0.97	0.96	0.95	0.94	0.8	0.27	0.97	0.69	0.81	0.73
Total Stockholder Equity	0.98	0.71	0.9		0.89	0.93	0.86	-0.25	-0.62	0.81	0.89	0.84	0.79	0.79	0.89	0.66	0.88	0.81	0.94	0.89	0.62	0.58	0.94	0.84	0.87	0.71
Other Liab	0.94	0.92	0.93	0.89		0.96	0.79	-0.27	-0.86	0.83	0.81	0.74	0.69	0.69	0.88	0.5	0.93	0.84	0.95	0.96	0.9	0.25	0.95	0.72	0.88	0.63
Net Tangible Assets	0.95	0.88	0.93	0.93	0.96		0.77	-0.36	-0.85	0.86	0.84	0.71	0.66	0.79	0.91	0.48	0.93	0.88	0.92	0.99	0.84	0.38	0.93	0.68	0.83	0.73
Property Plant And Equipment Net	0.85	0.53	0.69	0.86	0.79	0.77		0.12	-0.43	0.49	0.57	0.98	0.98	0.48	0.59	0.92	0.71	0.49	0.84	0.69	0.53	0.65	0.81	0.85	0.96	0.49
Net Debt	-0.26	-0.43	-0.43	-0.25	-0.27	-0.36	0.12		0.53	-0.6	-0.55	0.23	0.29	-0.73	-0.5	0.41	-0.41	-0.58	-0.18	-0.44	-0.35	-0.03	-0.25	0.13	0.06	-0.44
Retained Earnings	-0.71	-0.96	-0.84	-0.62	-0.86	-0.85	-0.43	0.53		-0.81	-0.67	-0.32	-0.27	-0.66	-0.8	-0.04	-0.86	-0.85	-0.73	-0.9	-0.97	0.06	-0.77	-0.32	-0.59	-0.63
Accounts Payable	0.87	0.81	0.95	0.81	0.83	0.86	0.49	-0.6	-0.81		0.92	0.43	0.35	0.9	0.97	0.16	0.89	0.98	0.85	0.89	0.72	0.17	0.89	0.57	0.62	0.66
Cash	0.89	0.74	0.89	0.89	0.81	0.84	0.57	-0.55	-0.67	0.92		0.54	0.47	0.89	0.95	0.32	0.85	0.9	0.83	0.85	0.58	0.37	0.86	0.64	0.62	0.68
Non Current Assets Total	0.81	0.45	0.62	0.84	0.74	0.71	0.98	0.23	-0.32	0.43	0.54		0.99	0.39	0.54	0.94	0.63	0.42	0.82	0.62	0.44	0.63	0.77	0.91	0.93	0.41
Non Currrent Assets Other	0.76	0.4	0.56	0.79	0.69	0.66	0.98	0.29	-0.27	0.35	0.47	0.99		0.34	0.46	0.97	0.57	0.34	0.76	0.56	0.4	0.66	0.71	0.85	0.91	0.37
Other Assets	0.78	0.66	0.85	0.79	0.69	0.79	0.48	-0.73	-0.66	0.9	0.89	0.39	0.34		0.87	0.21	0.79	0.87	0.71	0.8	0.53	0.46	0.75	0.45	0.52	0.66
Cash And Short Term Investments	0.93	0.83	0.97	0.89	0.88	0.91	0.59	-0.5	-0.8	0.97	0.95	0.54	0.46	0.87		0.28	0.93	0.98	0.9	0.93	0.73	0.25	0.93	0.65	0.7	0.75
Net Receivables	0.6	0.19	0.38	0.66	0.5	0.48	0.92	0.41	-0.04	0.16	0.32	0.94	0.97	0.21	0.28		0.4	0.14	0.6	0.37	0.18	0.74	0.54	0.77	0.8	0.26
Common Stock Shares Outstanding	0.93	0.86	0.97	0.88	0.93	0.93	0.71	-0.41	-0.86	0.89	0.85	0.63	0.57	0.79	0.93	0.4		0.92	0.92	0.95	0.83	0.32	0.95	0.65	0.82	0.84
Short Term Investments	0.87	0.84	0.96	0.81	0.84	0.88	0.49	-0.58	-0.85	0.98	0.9	0.42	0.34	0.87	0.98	0.14	0.92		0.85	0.91	0.76	0.15	0.89	0.54	0.63	0.75
Non Current Liabilities Total	0.99	0.79	0.95	0.94	0.95	0.92	0.84	-0.18	-0.73	0.85	0.83	0.82	0.76	0.71	0.9	0.6	0.92	0.85		0.9	0.76	0.34	1.0	0.86	0.93	0.65
Capital Surpluse	0.92	0.92	0.94	0.89	0.96	0.99	0.69	-0.44	-0.9	0.89	0.85	0.62	0.56	0.8	0.93	0.37	0.95	0.91	0.9		0.87	0.3	0.92	0.62	0.78	0.75
Other Current Assets	0.72	0.96	0.8	0.62	0.9	0.84	0.53	-0.35	-0.97	0.72	0.58	0.44	0.4	0.53	0.73	0.18	0.83	0.76	0.76	0.87		-0.07	0.78	0.4	0.69	0.55
Other Stockholder Equity	0.45	0.01	0.27	0.58	0.25	0.38	0.65	-0.03	0.06	0.17	0.37	0.63	0.66	0.46	0.25	0.74	0.32	0.15	0.34	0.3	-0.07		0.33	0.46	0.46	0.43
Total Liab	0.99	0.81	0.97	0.94	0.95	0.93	0.81	-0.25	-0.77	0.89	0.86	0.77	0.71	0.75	0.93	0.54	0.95	0.89	1.0	0.92	0.78	0.33		0.82	0.9	0.68
Long Term Investments	0.84	0.41	0.69	0.84	0.72	0.68	0.85	0.13	-0.32	0.57	0.64	0.91	0.85	0.45	0.65	0.77	0.65	0.54	0.86	0.62	0.4	0.46	0.82		0.85	0.44
Property Plant And Equipment Gross	0.9	0.67	0.81	0.87	0.88	0.83	0.96	0.06	-0.59	0.62	0.62	0.93	0.91	0.52	0.7	0.8	0.82	0.63	0.93	0.78	0.69	0.46	0.9	0.85		0.55
Preferred Stock Total Equity	0.7	0.56	0.73	0.71	0.63	0.73	0.49	-0.44	-0.63	0.66	0.68	0.41	0.37	0.66	0.75	0.26	0.84	0.75	0.65	0.75	0.55	0.43	0.68	0.44	0.55

Click cells to compare fundamentals

Arcus Biosciences Account Relationship Matchups

Arcus Biosciences balance sheet Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Total Assets	772.3M	1.6B	1.3B	1.1B	1.2B	822.9M
Other Current Liab	31.4M	52.0M	73M	65M	122M	128.1M
Total Current Liabilities	121.7M	166.1M	193M	184M	226M	115.9M
Total Stockholder Equity	502.3M	841.5M	657M	462M	485M	440.0M
Other Liab	16.6M	133.1M	467.5M	378M	434.7M	456.4M
Net Tangible Assets	163.8M	502.3M	841.5M	657M	755.6M	793.3M
Property Plant And Equipment Net	23.6M	137.4M	35M	51M	47M	40.9M
Net Debt	(158.2M)	(31.0M)	(86M)	(116M)	(102M)	(107.1M)
Retained Earnings	(328.2M)	(275.4M)	(542M)	(849M)	(1.1B)	(1.1B)
Accounts Payable	15.7M	10.3M	20M	17M	18M	11.8M
Cash	173.4M	147.9M	206M	127M	150M	134.1M
Non Current Assets Total	37.2M	910.6M	278M	264M	134M	204.6M
Non Currrent Assets Other	7.2M	591.2M	114M	106M	87M	111.1M
Other Assets	1.1M	25.7M	10.7M	14M	16.1M	8.5M
Cash And Short Term Investments	735.1M	681.3M	1.1B	759M	978M	612.4M
Net Receivables	1.7M	745M	43M	42M	20M	19M
Common Stock Shares Outstanding	54.8M	74.0M	72M	74M	90.1M	62.4M
Short Term Investments	555.2M	351.4M	803M	632M	828M	439.6M
Liabilities And Stockholders Equity	772.3M	1.6B	1.3B	1.1B	1.2B	822.9M
Non Current Liabilities Total	148.3M	584.4M	495M	449M	439M	266.9M
Capital Surpluse	357.9M	369.1M	830.4M	1.1B	1.3B	1.4B
Other Current Assets	1M	16M	15M	30M	38M	39.9M
Other Stockholder Equity	369.1M	830.4M	1.1B	(7M)	(8.1M)	(7.6M)
Total Liab	270.0M	750.4M	688M	633M	665M	382.9M
Long Term Investments	6.4M	182.0M	129M	107M	14M	13.3M
Property Plant And Equipment Gross	10.8M	155.2M	58M	82M	88M	53.1M
Total Current Assets	735.1M	681.3M	1.1B	831M	1.0B	618.3M
Accumulated Other Comprehensive Income	64K	44K	(1.3M)	(7M)	(6.3M)	(6.0M)
Non Current Liabilities Other	148.3M	584.4M	140M	142M	157M	143.6M
Common Stock	6K	7K	1.2B	1.3B	1.6B	1.7B
Property Plant Equipment	9.3M	10.8M	32.5M	135M	155.3M	163.0M
Current Deferred Revenue	74.6M	102.0M	97M	91M	85M	64.3M
Deferred Long Term Liab	15.8M	3.2M	4M	3M	2.7M	2.6M
Net Invested Capital	502.3M	841.5M	657M	462M	533M	487.9M
Net Working Capital	614.1M	1.1B	874M	647M	790M	632.1M
Short Term Debt	27.9M	53.8M	3M	11M	12.7M	18.0M
Capital Stock	6K	7K	1.2B	1.3B	1.6B	1.7B

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Arcus Stock Analysis

When running Arcus Biosciences' price analysis, check to measure Arcus Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Arcus Biosciences is operating at the current time. Most of Arcus Biosciences' value examination focuses on studying past and present price action to predict the probability of Arcus Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Arcus Biosciences' price. Additionally, you may evaluate how the addition of Arcus Biosciences to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Arcus Historical Balance Sheet

Arcus Biosciences Inventory

(162.54 Million)

About Arcus Balance Sheet Analysis

Arcus Biosciences Balance Sheet Chart

Total Assets

Total Current Liabilities

Total Stockholder Equity

Short Term Investments

Capital Lease Obligations

Arcus Biosciences balance sheet Correlations

Arcus Biosciences Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Arcus Biosciences balance sheet Accounts

Thematic Opportunities

Explore Investment Opportunities

Additional Tools for Arcus Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Liab	+ 1.0	Non Current Liabilities Total
Non Current Liabilities Total	+ 0.99	Total Assets
Total Liab	+ 0.99	Total Assets
Capital Surpluse	+ 0.99	Net Tangible Assets
Non Currrent Assets Other	+ 0.99	Non Current Assets Total
Total Stockholder Equity	+ 0.98	Total Assets

Other Current Assets	- 0.97	Retained Earnings
Retained Earnings	- 0.96	Other Current Liab
Capital Surpluse	- 0.9	Retained Earnings
Common Stock Shares Outstanding	- 0.86	Retained Earnings
Retained Earnings	- 0.86	Other Liab
Short Term Investments	- 0.85	Retained Earnings